scholarly journals The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer

Genes ◽  
2021 ◽  
Vol 12 (3) ◽  
pp. 440
Author(s):  
Yue Cheng ◽  
Meiqi Wang ◽  
Junliang Zhou ◽  
Huanhuan Dong ◽  
Shuqing Wang ◽  
...  

N6-methyladenosine (m6A) is one of the most prevalent epigenetic modifications of eukaryotic RNA. The m6A modification is a dynamic and reversible process, regulated by three kinds of regulator, including m6A methyltransferases, demethylases and m6A-binding proteins, and this modification plays a vital role in many diseases, especially in cancers. Accumulated evidence has proven that this modification has a significant effect on cellular biological functions and cancer progression; however, little is known about the effects of the m6A modification in non-small cell lung cancer (NSCLC). In this review, we summarized how various m6A regulators modulate m6A RNA metabolism and demonstrated the effect of m6A modification on the progression and cellular biological functions of NSCLC. We also discussed how m6A modification affects the treatment, drug resistance, diagnosis and prognosis of NSCLC patients.

2019 ◽  
Vol 8 (1) ◽  
pp. 203-211
Author(s):  
Fei Gao ◽  
Jun-Chi Xu ◽  
Xin-Ran You ◽  
Xin Gao ◽  
Jia-Ling Wei ◽  
...  

2021 ◽  
Vol 25 (6) ◽  
pp. 2994-3005
Author(s):  
Ying Lu ◽  
Shanshan Yu ◽  
Guangxue Wang ◽  
Zuan Ma ◽  
Xuelian Fu ◽  
...  

2018 ◽  
Vol 51 (4) ◽  
pp. 1839-1851 ◽  
Author(s):  
Mingfei Sun ◽  
Xianjie Zheng ◽  
Qingjiang Meng ◽  
Yanjun Dong ◽  
Guoyu Zhang ◽  
...  

Background/Aims: Lung cancer continues to be the leading cause of cancer related deaths worldwide due to its high incidence, malignant behavior and lack of major advancements in treatment strategy. The occurrence and development of lung cancer is closely related to inflammation. Thus, we conducted the present study to investigate the effects of IL-35 (Interleukin 35), a newly identified anti-inflammatory factor, on non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers. Methods: We first evaluated the IL-35 expression in 384 pairs of NSCLC samples and their adjacent normal mucosa by realtime PCR, ELISA (Enzyme-linked immunoassay) and tissue microarrays. Then the role of IL-35 on patient survival rates, cancer progression and their sensitivity to chemotherapy drugs were assessed. Results: IL-35 was barely expressed in the NSCLC tissues but highly expressed in the adjacent normal tissues. The down-regulation of IL-35 was significantly correlated with the results of American Joint Committee on Cancer stage, differentiation and it was also shown to be an independent prognostic indicator of disease-free survival and overall survival for patients with NSCLC. Overexpression of IL-35 in NSCLC cells suppressed cell migration, invasion, proliferation, colony formation through suppressing β-catenin. IL-35 inhibited NSCLC formation in the mice model and sensitize the cancer cells to chemotherapy drugs. Conclusion: Our results showed that IL-35 plays an inhibitory role in NSCLC development and function as a novel prognostic indicator and a potential therapeutic target.


Cancer ◽  
2013 ◽  
Vol 120 (5) ◽  
pp. 652-663 ◽  
Author(s):  
Guang-Yin Zhao ◽  
Jian-Yong Ding ◽  
Jie Gu ◽  
Chun-Lai Lu ◽  
Zong-Wu Lin ◽  
...  

2021 ◽  
Vol Volume 13 ◽  
pp. 75-87
Author(s):  
Qingshan Ma ◽  
Baogang Huai ◽  
Yuting Liu ◽  
Zhongyao Jia ◽  
Qilong Zhao

Sign in / Sign up

Export Citation Format

Share Document